Table 2.

Changes of clinical parameters in GD group before and after treatment (n = 37)

	GDT0	GDT3	p value
BMI (kg/m2)	21.09(19.36–23.15)	22.76(20.73–24.73)	<0.0001∗∗∗∗
FT3 (pg/mL)	15.65(9.97–48.83)	2.94(2.64–11.56)	<0.0001∗∗∗∗
FT4 (ng/dL)	4.52(3.38–11.66)	1.06(0.84–3.65)	<0.0001∗∗∗∗
TSH (μIU/mL)	0.0025(0.0025–0.0060)	0.987(0.0025–2.930)	0.0017∗∗
TRAb (U/L)	4.90(3.05–8.7)	3.00(1.15–8.15)	0.9101
TPO-Ab (IU/mL)	128.3(21.87–299.50)	117.2(16.25–250.60)	0.1071
Tg-Ab (IU/mL)	246.3(65.38–725.1)	90.20(17.42–488.10)	0.0229∗

GDT0,GD group before drug treatment; GDT3,GD group after 3 months of drug treatment.